And, Filippo, I'll just talk a bit about what we're continuing to see from competition and then your question on household and what we're seeing out there. Largely consistent with this. We've seen ...

Together, this combination is expected to reduce historical mobile volatility, strengthen our competitive position, enhance our broad market capabilities, and expand our TAM into dispense and ...

Good afternoon, everyone, and welcome to the Conference Call for Demant's 2025 Annual Results. My name is Peter Pudselykke, and I'm heading up the Investor Relations activities here in Demant. With me ...

This dual experimental-numerical approach provides a rare, holistic view of bonded joint performance under ballistic loading, ...

BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from ...